Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

927
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
927
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

1.2K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.2K
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

907
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
907
Altered States of Awareness01:06

Altered States of Awareness

1.4K
Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
1.4K
Drug Classes and Categories01:25

Drug Classes and Categories

3.4K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
3.4K
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

964
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
964

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report.

Pharmacotherapy·2026
Same author

Prevalence and Patterns of Non-Medical Gabapentinoid Use in a General Population Sample: Findings From the Australian National Drug Strategy Household Survey.

Drug and alcohol review·2026
Same author

Recent Medicare rebates for key pharmacogenomic tests: advancing equitable access to prevent serious drug reactions.

Internal medicine journal·2026
Same author

The effect of daily aerobic cycling exercise on cannabis withdrawal: An inpatient randomised controlled trial.

Scientific reports·2026
Same author

Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non-Prescription Drug Assessment Unit.

British journal of clinical pharmacology·2025
Same author

A 3-year experience of an Australian short-stay Psychiatric, Alcohol and Non-prescription Drug Assessment Unit: unit activity and the patient experience.

Emergency medicine journal : EMJ·2025

Related Experiment Video

Updated: Mar 26, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

657

Medicinal cannabis.

Bridin Murnion1

  • 1Senior staff specialist, Drug Health Services, Royal Prince Alfred Hospital.

Australian Prescriber
|February 5, 2016
PubMed
Summary

Cannabis derivatives show potential for treating conditions like multiple sclerosis and cancer pain, but conclusive evidence is lacking. Regulatory frameworks are needed to ensure safe therapeutic use of cannabinoids.

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Regulatory Science

Background:

  • Preclinical research suggests therapeutic applications for cannabis and its derivatives.
  • Potential indications include multiple sclerosis spasticity/pain, cancer-associated nausea/vomiting, cancer pain, and HIV neuropathy.

Purpose of the Study:

  • To review the postulated therapeutic uses of cannabis derivatives.
  • To examine the limitations of current evidence and controversies surrounding cannabinoid product regulation.
  • To highlight the need for a regulatory and educational framework for therapeutic cannabinoid introduction.

Main Methods:

  • Literature review of preclinical and clinical investigations on cannabis therapeutics.
  • Analysis of existing regulatory status and proposed legislation in Australia.
Keywords:
cannabidioldrug regulationmedical marijuananabiximols

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.2K
Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

7.1K

Related Experiment Videos

Last Updated: Mar 26, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

657
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.2K
Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

7.1K

Main Results:

  • Evidence for therapeutic efficacy is limited, often subjective, and inconclusive.
  • Significant controversies exist regarding cannabinoid product production, supply, and administration.
  • Nabiximols is currently the only cannabinoid listed on the Australian Register of Therapeutic Goods; cannabidiol is recommended for Schedule 4 inclusion.

Conclusions:

  • While preclinical data is promising, robust clinical evidence for cannabis therapeutics is insufficient.
  • A comprehensive regulatory and educational framework is essential for the safe integration of cannabinoids into medical practice.
  • Australian legislation, such as the Regulator of Medicinal Cannabis Bill 2014, aims to address these regulatory gaps.